[Use of collagen-polyvinylpirrolidone in the treatment of Parry-Romberg syndrome.].

Background: Parry-Romberg syndrome is characterized by the presence of progressive hemifacial atrophy that affects the growth and development of structures on one side of the face. Our objective was to introduce collagen-polyvinylpirrolidone as a new therapeutic option for Parry-Romberg syndrome in two clinical cases. Clinical cases: two women, aging 56 and 28 years old, with facial hypocrhomic lesions, and right and left fronto-malar sunken area respectively, treated with topic steroids + penicilamina, fat grafts and silicone implants without improvement. We used collagen-polyvinylpirrolidone and they showed improvement: after six months there were not clinical or esthetical complications. Conclusions: collagen-polivinilpirrolidone could be a new therapeutic option for Parry-Romberg syndrome with good clinical and esthetical results. It is easy to apply and it has few side effects and without complications.